# EDGAR Filing Document

**Accession Number:** 0001691082
**File Stem:** 0001193125-25-200401
**Filing Date:** 2025-9
**Character Count:** 38294
**Document Hash:** e7f90c544ea7e46e00ea237af5973fac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-200401.hdr.sgml**: 20250911

**ACCESSION NUMBER**: 0001193125-25-200401

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250911

**DATE AS OF CHANGE**: 20250910

**EFFECTIVENESS DATE**: 20250911

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LB PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001691082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290180
- **FILM NUMBER:** 251306956

**BUSINESS ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 917-450-6581

**MAIL ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LB PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20161129

**As filed with the Securities and Exchange Commission on September 10, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## LB Pharmaceuticals Inc
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-1854347** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **One Pennsylvania Plaza, Suite 1025**<br> **New York, NY** | **10119** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**LB Pharmaceuticals Inc 2017 Stock Incentive Plan** 

**LB Pharmaceuticals Inc 2018 Stock Incentive Plan** 

**LB Pharmaceuticals Inc 2023 Stock Incentive Plan** 

**LB Pharmaceuticals Inc 2025 Equity Incentive Plan** 

**LB Pharmaceuticals Inc 2025 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**Heather Turner** 

**Chief Executive Officer** 

**LB Pharmaceuticals Inc** 

**One Pennsylvania Plaza, Suite 1025** 

**New York, NY 10119** 

**Tel: (212) 605-0300**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Divakar Gupta** 

**Brandon Fenn** 

**Marc Recht** 

**Minkyu Park** 

**Cooley LLP** 

**55 Hudson Yards** 

**New York, NY 10001** 

**Tel: (212) 479-6000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS** 

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the "Securities Act") and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Documents by Reference.** <br>

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

(a) Amendment No. 
1 to the Registrant's Registration Statement on [Form S-1](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080ds1a.htm) filed with the Commission on September 8, 2025
(File No. 333-289812), which contains the audited financial statements for the Registrant's latest fiscal year for which such statements have been filed;

(b) The Registrant's prospectus to be filed with the Commission on or about September 11, 2025 pursuant
to Rule 424(b) of the Securities Act relating to the Registration Statement on [Form S-1](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080ds1a.htm) , as amended (File No. 333-289812); and

(c) The description of the Registrant's Common Stock contained in the Registrant's Registration
Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1691082/000119312525198793/d74445d8a12b.htm) filed on September 9, 2025 (File No. 001-42831) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such
description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**Item 4.** **Description of Securities.** <br>

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.** <br>

Not applicable.

------

**Item 6.** **Indemnification of Directors and Officers.** <br>

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant's amended and restated certificate of incorporation permits indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant's amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit it to indemnify its other officers, employees, and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

The Registrant has entered into indemnification agreements with its directors and executive officers, whereby it has agreed to indemnify its directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee or agent of the Registrant, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act, that might be incurred by any director or officer in his capacity as such.

**Item 7.** **Exemption from Registration Claimed.** <br>

Not applicable.

**Item 8.** **Exhibits.** <br>

The exhibits to this Registration Statement are listed below:

------

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended and as currently in effect (incorporated herein by reference to Exhibit 3.2 to the Registrant's Registration Statement on Form S-1/A (File No. 333-289812), filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Form of Amended and Restated Certificate of Incorporation of the Registrant, to be effective immediately prior to the closing of the Registrant's initial public offering (incorporated herein by reference to Exhibit 3.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex33.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.5 | [Form of Amended and Restated Bylaws of the Registrant, to be effective immediately prior to the closing of the Registrant's initial public offering (incorporated herein by reference to Exhibit 3.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex34.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.6 | [Form of Common Stock Certificate of the Registrant (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-289812), filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080dex41.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Cooley LLP.](d946090dex51.htm) |
| 23.1\* | [Consent of BDO USA, P.C., Independent Registered Public Accounting Firm](d946090dex231.htm) |
| 23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](d946090dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page).](d946090ds8.htm#sig) |
| 99.1 | [2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex101.htm) |
| 99.2 | [Form of Option Grant Notice and Agreement, Exercise Notice, and Restricted Stock Award Notice under the 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex102.htm) |
| 99.3 | [2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex103.htm) |
| 99.4 | [Form of Option Grant Notice and Agreement, Exercise Notice, and Restricted Stock Award Notice under the 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex104.htm) |
| 99.5 | [2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August, 22 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex105.htm) |
| 99.6 | [Amendment No. 1 to 2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex106.htm) |
| 99.7 | [Form of Option Grant Notice and Agreement, Exercise Notice, and Restricted Stock Award Notice under the 2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex107.htm) |
| 99.8 | [2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant's Registration Statement on Form S-1/A (File No. 333-289812), filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080dex108.htm) |

---

------

---

| | |
|:---|:---|
| 99.9 | [Form of Option Grant Notice and Agreement and Exercise Notice under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registrant's Registration Statement on Form S-1/A (File No. 333-289812), filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080dex109.htm) |
| 99.10 | [Form of RSU Award Grant Notice and Agreement under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant's Registration Statement on Form S-1/A, as amended (File No. 333-289812), filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080dex1010.htm) |
| 99.11 | [2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrant's Registration Statement on Form S-1/A (File No. 333-289812), filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/1691082/000119312525197877/d12080dex1011.htm) |
| 107\* | [Filing Fee Table.](d946090dexfilingfees.htm) |

---

\* Filed herewith.

**Item 9.** **Undertakings.** <br>

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table
in the effective Registration Statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the
Registration Statement or any material change to such information in the Registration Statement.

*Provided, however,* that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.

------

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 10, 2025.

---

| | |
|:---|:---|
| **LB PHARMACEUTICALS INC** | **LB PHARMACEUTICALS INC** |
| By: | /s/ Heather Turner |
|  | Heather Turner |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Heather Turner and Marc Panoff and each of them, as his or her true and lawful attorney-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Heather Turner<br> Heather Turner | Chief Executive Officer and Director<br> (*Principal Executive Officer)* | September 10, 2025 |
| /s/ Marc Panoff<br> Marc Panoff | Senior Vice President, Finance<br> (*Principal Financial and Accounting Officer*) | September 10, 2025 |
| /s/ Scott Garland<br> Scott Garland | Chairman of the Board of Directors | September 10, 2025 |
| /s/ Rajul Jain, M.D.<br> Rajul Jain, M.D. | Director | September 10, 2025 |
| /s/ Rebecca Luse<br> Rebecca Luse | Director | September 10, 2025 |
| /s/ Ran Nussbaum<br> Ran Nussbaum | Director | September 10, 2025 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Zachary Prensky<br> Zachary Prensky | Director | September 10, 2025 |
| /s/ Robert R. Ruffolo, Jr., Ph.D., D.Sc. (h), D.Eng. (h), F.C.P.P.<br> Robert R. Ruffolo, Jr., Ph.D., D.Sc. (h), D.Eng. (h), F.C.P.P. | Director | September 10, 2025 |
| /s/ Chen Yu, M.D.<br> Chen Yu, M.D. | Director | September 10, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g946090g0910044554271.jpg)

Divakar Gupta

+1 (212) 479-6474

dgupta@cooley.com

September 10, 2025

LB Pharmaceuticals Inc

One Pennsylvania Plaza, Suite 1025

New York, NY 10119

Ladies and Gentlemen:

We have acted as counsel to LB Pharmaceuticals Inc, a Delaware corporation (the "***Company***"), in connection with the filing of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering by the Company of up to 3,565,868 shares (the "***Shares***") of its common stock, par value $0.0001 per share ("***Common Stock***"), consisting of (a) 10,397 shares of Common Stock issuable pursuant to the Company's 2017 Stock Incentive Plan (the "***2017 Plan***"), (b) 27,943 shares of Common Stock issuable pursuant to the Company's 2018 Stock Incentive Plan (the "***2018 Plan***"), (c) 419,193 shares of Common Stock issuable pursuant to the Company's 2023 Stock Incentive Plan (the "***2023 Plan***"), (d) 2,907,335 shares of Common Stock issuable pursuant to the Company's 2025 Equity Incentive Plan (the "***2025 Plan***"), and (e) 201,000 shares of Common Stock issuable pursuant to the Company's 2025 Employee Stock Purchase Plan (together with the 2017 Plan, the 2018 Plan, the 2023 Plan, and the 2025 Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plans, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Cooley LLP 55 Hudson Yards New York, NY 10001

t: +1 (212) 479-6000 f: +1 (212) 479-6275 cooley.com

------

![LOGO](g946090g0910044554271.jpg)

LB Pharmaceuticals Inc

September 10, 2025

Page Two

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

---

| | |
|:---|:---|
| By: | /s/ Divakar Gupta |
|  | Divakar Gupta |

---

Cooley LLP 55 Hudson Yards New York, NY 10001

t: +1 (212) 479-6000 f: +1 (212) 479-6275 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

<u>Consent of Independent Registered Public Accounting Firm</u> 

We hereby consent to the incorporation by reference in this Registration Statement of our report dated June 27, 2025, except for the effects of the reverse stock split described in Note 15, as to which the date is September 8, 2025, relating to the financial statements of LB Pharmaceuticals Inc (the Company) appearing in the Company's Registration Statement on Form S -1 (No. 333-289812). Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

/s/ BDO USA, P.C.

New York, New York

September 10, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**LB PHARMACEUTICALS INC**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2017 Stock Incentive Plan | Other | 10397 | $49.81 | $517874.57 | 0.0001531 | $79.29 |
| 2 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2018 Stock Incentive Plan | Other | 27943 | $66.40 | $1855415.20 | 0.0001531 | $284.07 |
| 3 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2023 Stock Incentive Plan | Other | 419193 | $41.80 | $17522267.40 | 0.0001531 | $2682.66 |
| 4 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2025 Equity Incentive Plan | Other | 2907335 | $15.00 | $43610025.00 | 0.0001531 | $6676.70 |
| 5 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2025 Employee Stock Purchase Plan | Other | 201000 | $12.75 | $2562750.00 | 0.0001531 | $392.36 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $66068332.17  |  | $10115.08  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $10115.08  |

---

 **Offering Note** <br>

<sup>1</sup> (1a) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock ("Common Stock") of LB Pharmaceuticals Inc (the "Registrant") that become issuable under the Registrant's 2017 Stock Incentive Plan (the "2017 Plan"), the Registrant's 2018 Stock Incentive Plan (the "2018 Plan"), the Registrant's 2023 Stock Incentive Plan (the "2023 Plan"), the Registrant's 2025 Equity Incentive Plan (the "2025 Plan"), or the Registrant's 2025 Employee Stock Purchase Plan (the "2025 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction. (1b) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price for the 10,397 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2017 Plan are calculated using the weighted-average exercise price of $49.81 per share for such stock options. (1c) Represents shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2017 Plan. No additional stock awards will be granted under the 2017 Plan. The shares of common stock reserved for issuance pursuant to such stock options will become available for issuance under the 2025 Plan to the extent any such shares (i) are not issued because such stock option or any portion thereof expires or otherwise terminates without all of the shares covered by such stock option having been issued, (ii) are not issued because such stock option or any portion thereof is settled in cash, (iii) are forfeited back to or repurchased by the Registrant because of the failure to meet a contingency or condition required for the vesting of such shares, (iv) are withheld or reacquired to satisfy the exercise, strike, or purchase price, or (v) are withheld or reacquired to satisfy a tax withholding obligation. See footnote 4b below.

<sup>2</sup> (2a) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price for the 27,943 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2018 Plan are calculated using the weighted-average exercise price of $66.40 per share for such stock options. (2b) Represents shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2018 Plan. No additional stock awards will be granted under the 2018 Plan. The shares of common stock reserved for issuance pursuant to such stock options will become available for issuance under the 2025 Plan to the extent any such shares (i) are not issued because such stock option or any portion thereof expires or otherwise terminates without all of the shares covered by such stock option having been issued, (ii) are not issued because such stock option or any portion thereof is settled in cash, (iii) are forfeited back to or repurchased by the Registrant because of the failure to meet a contingency or condition required for the vesting of such shares, (iv) are withheld or reacquired to satisfy the exercise, strike, or purchase price, or (v) are withheld or reacquired to satisfy a tax withholding obligation. See footnote 4b below.

<sup>3</sup> (3a) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price for the 419,193 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2023 Plan are calculated using the weighted-average exercise price of $41.80 per share for such stock options. No additional stock awards will be granted under the 2023 Plan. (3b) Represents shares of Common Stock reserved for issuance upon the exercise of outstanding stock options granted under the 2023 Plan. No additional stock awards will be granted under the 2023 Plan. The shares of common stock reserved for issuance pursuant to such stock options will become available for issuance under the 2025 Plan to the extent any such shares (i) are not issued because such stock option or any portion thereof expires or otherwise terminates without all of the shares covered by such stock option having been issued, (ii) are not issued because such stock option or any portion thereof is settled in cash, (iii) are forfeited back to or repurchased by the Registrant because of the failure to meet a contingency or condition required for the vesting of such shares, (iv) are withheld or reacquired to satisfy the exercise, strike, or purchase price, or (v) are withheld or reacquired to satisfy a tax withholding obligation. See footnote 4b below.

<sup>4</sup> (4a) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated on the basis of $15.00 per share (the "IPO Price"), as set forth in the Registrant's registration statement on Form S-1 (File No. 333-289812), as amended (the "S-1 Registration Statement"), that was declared effective on September 10, 2025. (4b) Represents 2,907,335 shares of Common Stock reserved for future grant under the 2025 Plan. The 2025 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2025 Plan on January 1st of each year, commencing on January 1, 2026 and ending on (and including) January 1, 2035, in an amount equal to five percent (5%) of the total number of shares of capital stock on a fully diluted basis on December 31 of the preceding year; provided, however, that the Registrant's board of directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock. This explanation is provided for information purposes only. The issuance of such additional shares is not being registered on this Registration Statement. In addition, to the extent that any stock options outstanding under the 2017, 2018 Plan, or 2023 Plan expire, terminate prior to exercise or settlement, are not issued because the award is settled in cash, are forfeited because of the failure to vest, or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, the shares of common stock reserved for issuance pursuant to such stock options will become available for issuance under the 2025 Plan. See footnotes 1c, 2b and 3b above.

<sup>5</sup> (5a) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated on the basis of the IPO Price, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2025 ESPP. (5b) Represents 201,000 shares of Common Stock reserved for future grant under the 2025 ESPP. The 2025 ESPP provides that an additional number of shares of Common Stock will automatically be added annually to the shares authorized for issuance under the 2025 ESPP on January 1st of each year, commencing on January 1, 2026 and ending on (and including) January 1, 2035, in an amount equal to the lesser of (i) one percent (1%) of the total number of shares of capital stock on a fully diluted basis on December 31st of the preceding calendar year and (ii) 402,000 shares of Common Stock; provided, however, that the Registrant's board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve for such calendar year or that the increase for such year will be a lesser number of shares of Common Stock than would otherwise occur. This explanation is provided for information purposes only. The issuance of such additional shares is not being registered on this Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---